Eledon Pharmaceuticals, Inc.
Nasdaq · Healthcare · Pharmaceutical Preparations · Irvine, CA
ELDN chart
What traders are saying about $ELDN
Latest postsEledon Pharmaceuticals, Inc. news
- NewcelX prices $1.55M share offering at $3.29 to fund diabetes program
TradingView ·
- Eledon Pharmaceuticals, Inc. (ELDN) Seasonal returns chart
Yahoo Finance UK ·
- VANGUARD CAPITAL MANAGEMENT LLC Adds 540,639 Shares of Eledon Ph
GuruFocus ·
- Eledon Pharmaceuticals Presents Phase 2 BESTOW Trial Data Showing Sustained Improvements in Quality of Life and Symptom Burden with Tegoprubart Compared to Tacrolimus at American Society of Nephrology Kidney Week 2026 Annual Meeting
Yahoo Finance ·
- Eledon Pharmaceuticals Announces Presentation at the American Society of Nephrology Kidney Week 2026 Annual Meeting
Yahoo Finance ·
- Eledon Presents Updated Long-Term Phase 2 BESTOW Extension Study Results at the International Congress of The Transplantation Society
Yahoo Finance ·
- Eledon Pharmaceuticals Announces Presentation at the International Congress of The Transplantation Society
Yahoo Finance ·
- Eledon Pharmaceuticals Announces Islet Cell Transplantation IND Submission, First Patients Enrolled in Multiple Transplant Programs, and Reaffirms Plan to Initiate Phase 3 Kidney Transplantation Trial in Fourth Quarter 2026
Yahoo Finance ·
- Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Yahoo Finance ·
- A Diabetes Therapy Just Locked In Its Cell Supplier, and the Race to End Insulin Injections Is Heating Up
Yahoo Finance ·
- NewcelX Appoints World-Renowned Diabetes Cure-Focused Pioneer, Dr. Camillo Ricordi, to Scientific Advisory Board
Yahoo Finance ·
- NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes
Yahoo Finance ·
Eledon Pharmaceuticals, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Net income | -$45.6M | -$36.2M | -$116.5M | -$88.0M |
| Diluted EPS | $-0.52 | $-0.66 | $-4.73 | $-6.16 |
| Total assets (year end) | $169.0M | $177.4M | $89.1M | $92.8M |
| Cash and equivalents (year end) | $22.8M | $20.5M | $4.6M | $56.4M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Eledon Pharmaceuticals, Inc.
- Ticker
- ELDN (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Irvine, CA
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1404281
- Former names
- Eledon Pharmaceuticals, Inc., Novus Therapeutics, Inc., Tokai Pharmaceuticals Inc
Frequently asked questions
What exchange is Eledon Pharmaceuticals, Inc. listed on?
Eledon Pharmaceuticals, Inc. trades on the Nasdaq under the ticker symbol ELDN.
What industry is Eledon Pharmaceuticals, Inc. in?
Eledon Pharmaceuticals, Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Eledon Pharmaceuticals, Inc. headquartered?
Eledon Pharmaceuticals, Inc.'s business address on file with the SEC is in Irvine, CA.
When does Eledon Pharmaceuticals, Inc.'s fiscal year end?
Eledon Pharmaceuticals, Inc.'s fiscal year ends on December 31.
How much revenue did Eledon Pharmaceuticals, Inc. report?
Eledon Pharmaceuticals, Inc. reported $0 in revenue for calendar year 2016, according to its SEC filings.